Drug intelligence / Profile preview

gDAC-A

Development stage: Preclinical
Lead developer: Kangpu Biopharmaceuticals
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics

Overview

gDAC-A is a preclinical degrader-antibody conjugate developed by Kangpu Biopharmaceuticals Ltd. for the treatment of autoimmune diseases. This innovative therapeutic approach combines the precise targeting capabilities of an antibody with the potent protein degradation machinery of a degrader molecule.

Targets

CRL4-CRBN (Cereblon-based E3 ubiquitin ligase complex)

Beyond the preview

Go deeper on gDAC-A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on gDAC-A.

Explore the full profile